1. Sabattini E, Bacci F, Sagramoso C, Pileri SA WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102:83–87.
2. Habermann TM New developments in the management of diffuse large B-cell lymphoma. Hematology 2012; 17(Suppl 1):S93–S97.
3. MabThera International Trial Group.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006
4. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy.A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT);González-Barca;Bone Marrow Transplant,2020
5. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era;Zhou;Blood,2014